Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tower Semiconductor partners with CMT Medical Technologies
“Tower’s superb technology and its leadership in the CIS X-ray area, combined with CMT’s leadership in digital X-ray imaging system allow both companies to target and expand into
“Tower’s superb technology and its leadership in the CIS X-ray area, combined with CMT’s leadership in digital X-ray imaging system allow both companies to target and expand into
The company believes that the tumor growth inhibition observed in pre-clinical studies is due to a specific binding of BL-2030 to CCL2. By inhibiting CCL2’s activity, BL-2030 impairs
Under the terms of the agreement, Axentis Pharma purchased from aRigen Pharmaceuticals an exclusive license for the development and commercialization of ARB-CF0223 worldwide except Japan and Korea. As
On March 1, 2007, Samaritan signed an exclusive licensing agreement with Shire Human Genetic Therapies to market and sell Elaprase in Greece and Cyprus. Since the launch of
The IDenta’s Ecstasy kit is said to be the only reliable kit on the market with no false positives and is currently being produced in Israel and marketed
The initiative includes a large multi-center clinical trial with University Hospitals of Cleveland, the University of Cincinnati, and the Clinical Neuroscience Center in Detroit, Michigan as the participating
Under the terms of the agreement, Keata will retain the facility’s approximately 175 employees operating the 85,000 sq ft facility. Concurrently, Keata will enter into supply agreements with
There was no apparent difference in efficacy between AZD6244 and temozolomide for the primary endpoint, progression free survival. Although some anti-tumor activity was detected, AstraZeneca, which licensed AZD6244
The cancer and cell biology division at Queensland Institute of Medical Research (QIMR) has discovered a new protein target that is critical to the genetic repair processes that
The Phase II clinical trial is a randomized, open-label, multi-arm, multi-center trial evaluating GI-5005 in combination with full duration standard of care, versus standard of care alone in